Oncolytics Biotech Inc.
ONC.TO
TSX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 112.92% | 85.73% | 101.72% | -14.78% | 0.38% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 84.84% | 32.03% | 38.45% | -28.75% | -22.42% |
| Operating Income | -84.84% | -32.03% | -38.45% | 28.75% | 22.42% |
| Income Before Tax | -96.20% | -37.67% | -52.23% | 16.03% | 7.87% |
| Income Tax Expenses | -- | 874.76% | -2,179.55% | -11.53% | -- |
| Earnings from Continuing Operations | -96.20% | -40.40% | -49.43% | 15.97% | 7.87% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -96.20% | -40.40% | -49.43% | 15.97% | 7.87% |
| EBIT | -84.84% | -32.03% | -38.45% | 28.75% | 22.42% |
| EBITDA | -85.23% | -32.24% | -38.71% | 28.81% | 22.47% |
| EPS Basic | -47.76% | -2.45% | -13.66% | 29.70% | 18.09% |
| Normalized Basic EPS | -47.70% | -0.39% | -15.70% | 29.77% | 18.12% |
| EPS Diluted | -37.17% | -2.45% | -13.66% | 29.70% | 11.76% |
| Normalized Diluted EPS | -47.70% | -0.39% | -15.70% | 29.77% | 18.12% |
| Average Basic Shares Outstanding | 32.68% | 37.04% | 31.55% | 19.59% | 12.48% |
| Average Diluted Shares Outstanding | 32.68% | 37.04% | 31.55% | 19.59% | 12.48% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |